Bitcoin and Ether price update

Bitcoin (BTC) was priced at US$94,127.01, up by 3.2 percent over 24 hours.

Bitcoin price performance, January 6, 2025.

Chart via TradingView.

Bitcoin started Monday strong, rising above US$92,000 in early trading before briefly breaking US$94,600, signaling a potential shift in near-term momentum after a bruising finish to 2025.

Research firm 10X said the move reflects a return to more normalized trading volumes and early signs of renewed institutional positioning at the start of the year. The firm notes that Bitcoin is holding above key moving averages, with the 21 day line emerging as a critical support level for maintaining upside bias.

It added that the shift suggests growing expectations for a push toward the US$100,000 level. The rebound follows three consecutive monthly declines — a historically rare pattern that has often preceded January recoveries.

“The strength across crypto and traditional safe havens reflects a rebalancing phase driven by geopolitical risk and liquidity positioning,” said Lacie Zhang, a research analyst at Bitget Wallet.

“In this setup, Bitcoin has room to push toward US$105,000, while Ethereum could test US$3,600, as traders balance inflation risks with crypto’s deflationary characteristics and long-term adoption narrative.’

Zhang said DeFi is currently driving significant growth, with protocols such as Uniswap (UNI) and Aave (AAVE) seeing benefits from improved governance, new revenue-sharing frameworks and institutional investor involvement.

“For large-cap altcoins, XRP and Solana stand out: XRP’s role in cross-border payments and improving regulatory clarity, combined with ETF inflows, could support price ranges of US$5 – US$10, while Solana’s high-throughput ecosystem and network expansion position it for US$500 – US$800 over the next growth phase.

“The renewed surge in memecoin activity reflects improving retail risk appetite,” she added. “It’s not a long-term thesis, but often a precursor to liquidity rotating into higher-quality, utility-driven altcoins as the cycle matures.”

Ether (ETH) was priced at US$3,239.82, up by 3.2 percent over the last 24 hours.

Altcoin price update

• XRP (XRP) was priced at US$2.31, up by 10.4 percent over 24 hours.

• Solana (SOL) was trading at US$137.92, up by three percent over 24 hours.

Today’s crypto news to know

Crypto investment products pull in US$47.2 billion in 2025

Global crypto exchange-traded products attracted US$47.2 billion in net inflows in 2025, falling just short of the prior year’s record despite a noticeable slowdown in Bitcoin demand, according to CoinShares.

Bitcoin-focused products added US$26.9 billion, a sharp drop from 2024 levels, as price weakness dampened inflows and modest interest emerged in short-bitcoin vehicles. The cooling in Bitcoin was offset by a surge into select altcoins, led by Ethereum products, which posted US$12.7 billion in inflows.

Meanwhile, XRP and Solana funds followed closely as each recorded multibillion-dollar inflows and triple-digit percentage growth year over year.

Japan signals crypto integration across traditional markets

Satsuki Katayama, Japan’s finance minister, has signaled stronger government backing for integrating digital assets into the country’s stock and commodities exchanges.

Speaking at the Tokyo Stock Exchange, she emphasized the role of exchanges in expanding public access to blockchain-based assets and modern investment tools. She pointed to the US experience with crypto-linked exchange-traded funds (ETFs) as a reference point, even as Japan currently lacks domestically listed crypto ETFs.

Katayama described 2026 as a “digital year,” pledging policy support for exchanges adopting advanced trading technologies. The remarks build on regulatory reforms already underway, including discussions on allowing banks to hold crypto assets and the approval of Japan’s first yen-pegged stablecoin.

Bitget’s tokenized stock milestone and TradFi launch

Bitget’s new Universal Exchange vision has reached two major milestones that signal a major shift in how digital and traditional assets are traded in one place. Bitget announced last week that its tokenized stock volume surpassed US$1 billion, with 95 percent of that total volume occurring in December alone.

Building on that momentum, and following a successful private beta with over 80,000 users, today Bitget officially opened its TradFi trading suite to the public, allowing customers access to 79 different instruments across forex, metals, indices and commodities. These products are traded as contracts for difference and are settled entirely in USDT, meaning crypto-native traders can execute macro strategies without leaving the platform or converting to fiat currency.

During the test phase, XAU/USD recorded over US$100 million in single-day trading volume, one of the highest daily figures observed during the beta.

“Traders want the flexibility to choose between assets in a unified ecosystem,” said Chen.

“They want the freedom to move between crypto and traditional markets as conditions change. TradFi going public is about giving them that accessibility in one place, without friction.”

The move signals a broader shift in how exchanges are evolving, not just as venues for speculation, but as comprehensive gateways to global markets under a unified trading experience.

1. HLS Therapeutics (TSX:HLS)

Year-on-year gain: 26.6 percent
Market cap: C$149.8 million
Share price: C$4.76

HLS Therapeutics focuses on drugs for cardiovascular and central nervous system problems, often through partnerships. The company specializes in acquiring and commercializing pharmaceuticals that address unmet needs, including Vascepa to reduce cardiovascular risk and Clozaril for treatment-resistant schizophrenia.

HLS in-licensed the exclusive rights to the treatments Nilemdo and Nexlizet, both of which are already approved in other countries, from Esperion (NASDAQ:ESPR) in May.

The November 2025 Health Canada approval of LDL-cholesterol lowering treatment Nilemdo represents the most significant catalyst for the company since the launch of Vascepa, positioning HLS as a dominant leader in the Canadian cardiovascular market. The company is targeting Nilemdo’s commercial launch in Q2 2026.

Along with the approval, Health Canada issued a notice of non-compliance for its Nexlizet cholesterol-reducing treatment. According to HLS, the decision was related to chemistry, manufacture and controls data, not clinical data or safety.

Additionally, the company generates revenue from a diversified portfolio of royalty interests on various products marketed by third parties.

2. Satellos Bioscience (TSXV:MSCL)

Year-on-year gain: 14.49 percent
Market cap: C$141.04 million
Share price: C$0.79

Satellos Bioscience is a Canadian pharmaceutical company expanding treatment options for muscle disorders. The company has focused specifically on Duchenne muscular dystrophy, developing therapies that target the specific biological pathways involved in regenerating and repairing muscle tissue.

Its lead candidate, SAT-3247, targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.

In Q4 2025, Satellos administered the first dose to a patient in its 11-month open-label follow-up study for adults who completed its initial Phase 1b trial. The study seeks to demonstrate the lasting impact of the significant functional improvements observed earlier in the year.

On December 9, the company received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) and several other global regulators to initiate BASECAMP, a global Phase 2 randomized, placebo-controlled study to evaluate SAT-3247 in pediatric patients.

3. Knight Therapeutics (TSX:GUD)

Year-on-year gain: 14.29 percent
Market cap: C$592.59 million
Share price: C$6.00

Knight Therapeutics is a specialty pharmaceutical company headquartered in Montreal, Québec. It operates on an acquisition and in-licensing model, obtaining the rights to innovative medicines from global pharmaceutical companies and commercializing them across Canada and Latin America.

The company was originally founded by the former leaders of Paladin Labs, which was acquired by Endo International in 2014. In June 2025, Knight bought the Paladin business back from Endo for C$107 million, adding over 40 products to Knight’s Canadian roster.

The additions, helped drive 32 percent revenue growth year-over-year to a record C$122.55 million in Q3. The company projects its Knight Canada subsidiary will be the company’s top revenue-contributor within two years.

4. BioSyent (TSXV:RX)

Year-on-year gain: 10.07 percent
Market cap: C$146.89 million
Share price: C$12.90

BioSyent is a specialty pharmaceutical company focused on in-licensing or acquiring established, high-margin healthcare products for the Canadian and international markets. Its growth is anchored by brands in iron health and women’s wellness. Its flagship brand, FeraMAX, has been Canada’s leading iron supplement for over a decade.

The company’s 2024 acquisition of Tibella, a treatment for menopausal symptoms, has been a major growth driver. According to its Q3 earnings report. BioSyent’s sales grew 19 percent year-over-year in Canada and 94 percent in the international market.

5. NurExone Biologic (TSXV:NRX)

Year-on-year gain: 6.45 percent
Market cap: C$47.54 million
Share price: C$0.66

NurExone Biologic is behind ExoTherapy, a drug-delivery platform that uses exosomes, which are nano-sized extracellular vesicles, to create treatments for central nervous system disorders, spinal cord injuries and traumatic brain injuries. It is a less invasive alternative to cell transplantation, which requires surgery and carries the risk of rejection.

NurExone’s first nano-drug, ExoPTEN, uses a proprietary sIRNA sequence delivered with the ExoTherapy platform to treat spinal cord injuries. ExoPTEN received orphan drug designation from the US FDA in October 2023.

The company expects to initiate its Phase 1/2a first-in-human trial for acute spinal cord injury in the second half of 2026, targeting patients with traumatic injuries.

It continues to make significant progress, with recent preclinical studies demonstrating strong, dose-dependent vision recovery in glaucoma models and improved motor function in spinal cord injury models.

The company announced plans for a US exosome production facility in Indianapolis, Indiana, in September. According to the release, ‘The GMP compliant site would produce exosomes both for NurExone’s therapeutic pipeline and for a growing business-to-business opportunity in regenerative aesthetics.’

In December, the company began planning for small-scale production of ExoPTEN in Israel to support its clinical trial.

Investor Insight

Centurion Minerals offers investors an early-stage entry point into a strategically located gold exploration company positioned within one of North America’s most prolific and active mining districts. With a restructured corporate foundation, and a highly experienced geological and corporate finance team, the company is primed for value-creating discoveries.

Overview

Centurion Minerals (TSXV:CTN) is a Canadian exploration company focused on the acquisition, exploration and development of precious metals projects in the Americas.

The company’s strategy is centered on advancing high-quality, early-stage gold assets through systematic exploration to define drill-ready targets and unlock the discovery potential inherent in its three-part claim package: the Newman, Noseworthy and Hepburn properties. Situated near major operations and new discoveries, these claims benefit from excellent infrastructure, year-round road access and proximity to proven mineralized structural corridors. Centurion intends to increase shareholder value through targeted geophysics, ground truthing and drilling programs designed to reveal new high-grade zones, as well as through potential future acquisitions of complementary gold assets across the Americas.

Backed by a leadership team with decades of exploration, geology, corporate finance and project development experience, Centurion is positioned to capitalize on strong gold market fundamentals and renewed investor interest in junior exploration companies. With a low current valuation and advancing work program, the company provides leverage to both exploration success and broader trends in the gold sector.

Company Highlights

• Highly prospective gold project in a world-class district located in the central north Abitibi greenstone belt, adjacent to major deposits and producing mines including Hecla Mining’s (NYSE:HL) Casa Berardi mine and Agnico Eagle’s (TSX:AEM) Detour Lake operations.
• Exceptional closeology advantage, with its Casa Berardi West project situated just 12 km from AMEX Exploration’s (TSXV:AMX) 1.6 Moz “Perron” discovery and along the same structural corridors that have produced multi-million-ounce deposits.
• Significant historic drilling across the three claim groups, including results up to 38 g/t gold and multiple intervals indicating gold-bearing iron formations and shear zones.
• Clear exploration strategy including historic data compilation, geophysical surveys, target generation and a planned program to define new mineralized zones.
• Experienced management and technical team with decades of experience in mineral exploration, and international corporate finance, enhances the potential of uncovering additional exploration opportunities.
• Low market capitalization and recently reactivated corporate structure, offering investors a low entry point ahead of meaningful upside catalysts.

Key Project

Casa Berardi West Gold Project

The Casa Berardi West project is Centurion’s flagship gold exploration asset, encompassing approximately 6,732 hectares across three contiguous claim groups – Newman, Noseworthy and Hepburn – located 66 km northeast of Cochrane, Ontario. The project sits along structural corridors that host some of the region’s most significant deposits, including Hecla Mining’s Casa Berardi mine (3 Moz past production, plus 4 Moz in reserves and resources), Agnico Eagle’s Detour Lake mine (15 Moz reserve, producing ~659,000 oz of gold per year ), and AMEX Exploration’s Perron discovery (1.6 Moz measured and indicated resource at 6.14 g/t gold).

Location of the three claim groups at Casa Berardi West

Geological Setting & Closeology Advantage

The project is situated within the central north Abitibi Subprovince, an Archean greenstone belt known globally for its prolific endowment of gold and base metals. The claims lie adjacent to geological features associated with multiple major deposits – iron formations, shear zones and VMS trends – creating strong analogues to high-grade gold mines such as the Musselwhite mine in Northern Ontario.

This “closeology” positioning significantly enhances the potential for Centurion’s ground to host similar mineralization.

Historic Results & Target Areas

Historic exploration across the Casa Berardi West project – spanning more than 70 RC and diamond drill holes – has already confirmed the presence of gold-bearing structures and favorable host rocks. Notably, previous work returned multiple samples above 1 g/t gold, including a standout result of 38 g/t gold, demonstrating strong mineralization potential across the claim area.

Significant historic drill results at Newman target

Across the three claim groups, drilling and geophysical surveys have identified key geological features associated with major deposits in the region, including iron formations, shear zones and sulphidized horizons. Several zones of interest remain untested or underexplored, particularly along structural trends that extend from nearby high-grade gold and VMS systems such as the Perron and Normetal areas.

These findings provide Centurion with multiple high-priority target areas for follow-up exploration, forming the foundation for its next phase of geophysical work and upcoming drill targeting.

Management Team

David Tafel – Director, President and CEO

David Tafel brings over 30 years of experience in corporate structuring, strategic planning, financing and executive management across multiple public and private resource companies. He has raised several hundred million dollars for ventures in mining, technology and life sciences, and previously managed private investment funds at Canada’s largest independent securities firm.

Jeremy Wright – Director and CFO

A seasoned financial executive with more than 20 years of experience, Jeremy Wright serves as president & CEO of Seatrend Strategy Group and has held CFO roles across numerous public companies in the resource and technology sectors. His background includes financial management, negotiations and environmental economics, supported by extensive board leadership experience.

Joseph Del Campo – Director

Joseph Del Campo has served as CFO and Interim CEO across several mining companies, including Unigold and First Nickel. With decades of corporate financial leadership and board experience, he contributes deep governance, audit and operational oversight expertise to Centurion’s board.

Mike Kilbourne – Geological Consultant

A veteran geologist with 40+ years of industry experience, Mike Kilbourne has managed over 100,000 metres of drilling across North America and Mexico, worked as a production geologist in multiple mining environments, and generated over 700 exploration targets for private and public companies.

Jamie Lavigne – Geological Consultant

Jamie Lavigne is a senior exploration geologist with more than 30 years of experience in base and precious metals. He has held senior technical roles with major mining companies and specializes in advanced exploration, resource delineation and geological modeling across global mineral belts.